Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
14th Jul 20157:00 amRNSHeadline Results from Pain Relief Study
13th Jul 20157:00 amRNSNotice of Pain Relief Portfolio Study Results
25th Jun 20157:00 amRNSCommencement of MED2002 Clinical Trial
17th Jun 20155:45 pmRNSResult of AGM
17th Jun 20157:00 amRNSAGM Statement
3rd Jun 20155:20 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20157:00 amRNSPain Relief Portfolio: Study Update
11th May 20157:00 amRNSBlock Listing Update
11th May 20157:00 amRNSBlue Diamond® Retail Roll-out
24th Apr 20153:00 pmRNSNotice of AGM
31st Mar 20155:05 pmRNSNotification of Major Interest in Shares
25th Mar 20157:00 amRNSPreliminary Results
18th Mar 20157:00 amRNSPain Relief Portfolio Study Commences
16th Mar 20155:48 pmRNSAIM Disclosure
3rd Mar 20154:52 pmRNSNotification of Major Interest in Shares
5th Feb 20157:00 amRNSUS Patent Extension for MED2002
2nd Feb 20151:18 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
28th Jan 20151:10 pmRNSNotification of Major Interest in Shares
23rd Jan 201510:14 amRNSNotification of Major Interest in Shares
22nd Jan 20152:33 pmRNSDirector Shareholding
15th Jan 201512:32 pmRNSNotification of Major Interest in Shares
15th Jan 201512:14 pmRNSDirector's Dealings
15th Jan 20157:00 amRNSNotice of Preliminary Results
5th Jan 20157:00 amRNSRemuneration of Non-Executive Directors
15th Dec 20147:00 amRNSAppointment of CRO for MED2002 Clinical Study
1st Dec 20147:00 amRNSUpdate on Pain Relief Clinical Programme
13th Nov 201410:02 amRNSDirectorate Change
11th Nov 20147:00 amRNSBlock Listing Update
10th Nov 20147:00 amRNSBlue Diamond Wins Market Share
9th Oct 201410:00 amRNSLaunch of CSD500 in the Netherlands and Belgium
16th Sep 20147:00 amRNSGrant of Options
11th Sep 20149:13 amRNSInterim Results Replacement
11th Sep 20147:00 amRNSInterim Results
8th Sep 20147:00 amRNSLicenses CSD500 in South Korea
15th Jul 20147:00 amRNSNotification of Interim Results
13th May 20145:30 pmRNSResult of AGM
13th May 20147:00 amRNSAGM Statement
28th Apr 20143:30 pmRNSBlock Listing Update
8th Apr 20147:00 amRNSNotice of AGM
7th Apr 201412:00 pmRNSNotification of Major Interest in Shares
7th Apr 201412:00 pmRNSNotification of Major Interest in Shares
1st Apr 201411:00 amRNSNotification of Major Interest in Shares
1st Apr 20147:00 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
31st Mar 201412:45 pmRNSNotification of Major Interest in Shares
28th Mar 20147:01 amRNSPreliminary Results
10th Mar 20147:01 amRNSCSD500: Launch Update
10th Mar 20147:00 amRNSPlacing to raise £12.0 million
7th Mar 20146:10 pmRNSPlacing to raise £12.0 million
26th Feb 20147:00 amRNSNotification of Preliminary Results
31st Jan 20149:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.